To include your compound in the COVID-19 Resource Center, submit it here.

Merck's Keytruda fails Phase III in second-line gastric cancer

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab (MK-3475) as second-line treatment missed the primary endpoints in the Phase III KEYNOTE-061 trial in previously treated patients with advanced gastric or gastroesophageal junction

Read the full 328 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE